Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Somatostatinoma 2Neoplasm Metastasis 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Adenoma, Islet Cell 2Vipoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Gastrointestinal Carcinoid Tumor 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1Adrenocortical Carcinoma 1Adenocarcinoma, Mucinous 1

Interventions

atezolizumab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Disulfides 1CTLA-4 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Bevacizumab × Endocrine × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡